Hyloris Developmentsen Sa Net Assets
Hyloris Developmentsen Sa net assets. Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has net assets worth €28.89 Million EUR (≈ $33.77 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€37.05 Million ≈ $43.32 Million USD) and total liabilities (€8.16 Million ≈ $9.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Hyloris Developmentsen Sa equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €28.89 Million |
| % of Total Assets | 77.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -45.57% |
| 10-Year Change | N/A |
| Growth Volatility | 16.35 |
Net Assets of Hyloris Developmentsen Sa (2016–2024)
Net assets of Hyloris Developmentsen Sa from 2016 to 2024. This chart illustrates how Hyloris Developmentsen Sa's net assets have evolved over time, based on quarterly financial data. See Hyloris Developmentsen Sa net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hyloris Developmentsen Sa (2016–2024)
The table below shows the annual net assets of Hyloris Developmentsen Sa from 2016 to 2024. For live market cap and overall valuation, see HYL market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €32.14 Million ≈ $37.58 Million |
-17.73% |
| 2023-12-31 | €39.07 Million ≈ $45.68 Million |
-29.02% |
| 2022-12-31 | €55.05 Million ≈ $64.35 Million |
+14.54% |
| 2021-12-31 | €48.06 Million ≈ $56.18 Million |
-18.63% |
| 2020-12-31 | €59.06 Million ≈ $69.05 Million |
+679.69% |
| 2019-12-31 | €-10.19 Million ≈ $-11.91 Million |
-128.33% |
| 2018-12-31 | €-4.46 Million ≈ $-5.22 Million |
-4.11% |
| 2017-12-31 | €-4.29 Million ≈ $-5.01 Million |
-95.89% |
| 2016-12-31 | €-2.19 Million ≈ $-2.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hyloris Developmentsen Sa's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6580100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Hyloris Developmentsen Sa Net Assets Breakdown (December 2024)
Hyloris Developmentsen Sa net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €140.00K | 0.44% |
| Other Comprehensive Income | €-3.52 Million | -10.94% |
| Other Components | €121.99 Million | 379.52% |
| Total Equity | €32.14 Million | 100.00% |
Hyloris Developmentsen Sa Competitors by Market Cap
The table below lists competitors of Hyloris Developmentsen Sa ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BINEX Co. Ltd
KQ:053030
|
$123.43 Million |
|
Silk Logistics Holdings Ltd
AU:SLH
|
$123.48 Million |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
$123.49 Million |
|
Trio-Tech International
NYSE MKT:TRT
|
$123.49 Million |
|
Mitrabara Adiperdana PT
JK:MBAP
|
$123.33 Million |
|
LiveWire Group Inc.
NYSE:LVWR
|
$123.29 Million |
|
Nykode Therapeutics ASA
OL:NYKD
|
$123.19 Million |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
$123.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyloris Developmentsen Sa's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,069,000 to 32,143,000, a change of -6,926,000 (-17.7%).
- Net loss of 6,342,000 reduced equity.
- Other comprehensive income decreased equity by 1,693,000.
- Other factors increased equity by 1,109,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.34 Million | -19.73% |
| Other Comprehensive Income | €-1.69 Million | -5.27% |
| Other Changes | €1.11 Million | +3.45% |
| Total Change | €- | -17.73% |
Book Value vs Market Value Analysis
This analysis compares Hyloris Developmentsen Sa's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-0.18 | €3.77 | x |
| 2018-12-31 | €-0.10 | €3.77 | x |
| 2019-12-31 | €-2.04 | €3.77 | x |
| 2020-12-31 | €2.29 | €3.77 | x |
| 2021-12-31 | €1.86 | €3.77 | x |
| 2022-12-31 | €1.98 | €3.77 | x |
| 2023-12-31 | €1.40 | €3.77 | x |
| 2024-12-31 | €1.11 | €3.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyloris Developmentsen Sa utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -63.15%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.29x
- Recent ROE (-19.73%) is below the historical average (-14.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -1745.07% | 0.05x | 0.00x | €-3.29 Million |
| 2018 | 0.00% | -6363.74% | 0.01x | 0.00x | €-5.57 Million |
| 2019 | 0.00% | -5795.60% | 0.02x | 0.00x | €-4.26 Million |
| 2020 | -12.10% | -4083.43% | 0.00x | 1.17x | €-13.05 Million |
| 2021 | -24.09% | -374.00% | 0.05x | 1.32x | €-16.38 Million |
| 2022 | -22.09% | -403.46% | 0.05x | 1.15x | €-17.30 Million |
| 2023 | -39.37% | -736.94% | 0.04x | 1.22x | €-19.29 Million |
| 2024 | -19.73% | -63.15% | 0.24x | 1.29x | €-9.56 Million |
Industry Comparison
This section compares Hyloris Developmentsen Sa's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,135,647,506
- Average return on equity (ROE) among peers: -21.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyloris Developmentsen Sa (HYL) | €28.89 Million | 0.00% | 0.28x | $123.41 Million |
| Argen-X (ARGX) | $66.65 Million | -33.73% | 0.67x | $47.46 Billion |
| BioSenic S.A. (BIOS) | $-6.76 Million | 0.00% | 0.00x | $1.57 Million |
| Celyad SA (CYAD) | $90.88 Million | -25.97% | 0.53x | $8.95 Million |
| Onward Medical N.V. (ONWD) | $48.05 Million | -74.34% | 0.62x | $153.63 Million |
| Oxurion NV (OXUR) | $35.28 Million | -28.73% | 0.06x | $62.21K |
| Tubize-Fin (TUB) | $443.43 Million | 0.00% | 0.18x | $7.82 Billion |
| UCB SA (UCB) | $7.27 Billion | 10.07% | 0.83x | $38.48 Billion |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more